✨ Free AI Report
Naurex Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Naurex Inc.
Company Research

Naurex Inc.: Business Overview, Financials & Competitive Analysis

Naurex Inc. scores 7/10 on the AskCyborg Cyborg Score (Solid). A well-executed biotech exit achieving significant clinical and commercial validation for novel CNS therapeutics. Naurex successfully developed a validated drug pipeline addressing a major unmet medical need in depression treatment with a differentiated mechanism. The $560M acquisition by a major pharmaceutical company validates the science and market opportunity, though the.

What is Naurex Inc.'s industry? Naurex Inc. operates in Neurology Drugs. AskCyborg classifies Naurex Inc. under Neurology Drugs in its company registry.

Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system. In July 2015, Allergan acquired Naurex in an all-cash trans...

7/ 10Solid

Cyborg Score thesis

A well-executed biotech exit achieving significant clinical and commercial validation for novel CNS...

Read the full analyst-debate transcript →
Industry Neurology Drugs
3 named competitors
1 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Naurex Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Naurex Inc.

AskCyborg analysts argue the bull and bear cases for Naurex Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Naurex Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Naurex Inc. Overview

Pro stress-test →

Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system. In July 2015, Allergan acquired Naurex in an all-cash transaction, which has since become part of AbbVie's portfolio. The company was founded as a Northwestern University spinout focused on rapid-acting antidepressant therapies with a differentiated mechanism of action.

Strategic Profile

Pro stress-test →

Naurex built a platform for discovering drugs that enhance synaptic plasticity through a novel mechanism that modulates the NMDA receptor, resulting in drugs that are both highly effective and well-tolerated. The lead candidate, rapastinel (GLYX-13), demonstrated rapid, substantial, and sustained antidepressant activity in Phase 2 studies without psychosis-like side effects.

Competitive Landscape

Pro stress-test →

Naurex competed in the antidepressant therapeutics market against established treatments and emerging competitors developing novel mechanisms for depression. The company's differentiated NMDA modulation approach with rapid onset and tolerability profile positioned it as an innovative alternative to traditional SSRIs and other CNS agents. Competitors in this space include companies developing ketamine derivatives, other glutamate modulators, and psychedelic-assisted therapies.

Industry Context

Naurex Inc. operates in Neurology Drugs.

Key facts

Founded: 2008 · Headquarters: Evanston, US · Employees: 9 · Revenue: $5.1M · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Naurex Inc..

  • Achieved rare clinical milestone: one of few Chicago-area drug companies to advance a candidate to Phase 3 trials before exit
  • Proprietary NMDA modulation platform addressed safety liability of competing mechanisms with demonstrated rapid efficacy
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • July 2015Acquired by Allergan plc for $560 million in all-cash transaction
Get alerted when Naurex Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Ketamine and derivativesEsketamine (Spravato) for treatment-resistant depression→Traditional SSRIsSertraline, escitalopram, and other established antidepressants→CNS therapeutics platformCentral nervous system disorder research and development→

Compare Naurex Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Naurex Inc. operates in Neurology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Neurology Drugs research →
NEW · MCP server

Ask your AI assistant about Naurex Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Naurex Inc. and its top competitor on Cyborg Score”
“What did Naurex Inc. do this quarter?”
“Is Naurex Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Naurex Inc. do?+
Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system. In July 2015, Allergan acquired Naurex in an all-cash trans...
What is Naurex Inc.'s Cyborg Score?+
Naurex Inc. has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Naurex Inc.'s main competitors?+
Named competitors include Ketamine and derivatives, Traditional SSRIs, CNS therapeutics platform. The full competitive landscape is in the AskCyborg report.
How can I get the full Naurex Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Naurex Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Naurex Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.